Další formáty:
BibTeX
LaTeX
RIS
@article{60470,
author = {Mráz, Marek},
address = {Washington DC, USA},
article_number = {20},
booktitle = {Blood},
doi = {http://dx.doi.org/10.1182/blood.2023022305},
keywords = {chronic lymphocytic leukemia; CD20 messenger RNA; alternative splicing; malignant B cells; anti-CD20 therapies},
language = {eng},
location = {Washington DC, USA},
pages = {1676-1678},
publisher = {American Society of Hematology},
title = {5′-UTR mRNA splicing determines CD20 levels},
url = {https://ashpublications.org/blood/article/142/20/1676/498635/5-UTR-mRNA-splicing-determines-CD20-levels},
year = {2023}
}
TY - JFULL
ID - 60470
AU - Mráz, Marek
PY - 2023
TI - 5′-UTR mRNA splicing determines CD20 levels
VL - 142
IS - 20
PB - American Society of Hematology
CY - Washington DC, USA
KW - chronic lymphocytic leukemia
KW - CD20 messenger RNA
KW - alternative splicing
KW - malignant B cells
KW - anti-CD20 therapies
UR - https://ashpublications.org/blood/article/142/20/1676/498635/5-UTR-mRNA-splicing-determines-CD20-levels
N2 - In this issue of Blood, Ang et al(1) show that human CD20 messenger RNA (mRNA) undergoes alternative splicing to generate distinct 5' untranslated region (5'-UTR) variants, which determine the cell-surface CD20 levels in malignant B cells and the interpatient variability in the expression of this therapeutic target. These variants can also be used as an escape mechanism from anti-CD20 therapies.
ER -
MRÁZ, Marek. 5′-UTR mRNA splicing determines CD20 levels. In \textit{Blood}. Washington DC, USA: American Society of Hematology, 2023, s.~1676-1678. 142. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2023022305.
|
